Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Peter Goedegebuure

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|December 26, 2022
Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancerHui Peng, Lijin Li, Chong Zuo, et al.
Oncoimmunology|September 20, 2018
Recruitment of CCR2<sup>+</sup> tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancerJulie G Grossman, Timothy M Nywening, Brian A Belt, et al.
Surgery|June 19, 2024
Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancersC Corbin Frye, Lena Tennant, Ashley Yeager, et al.
Annals of Surgical Oncology|October 25, 2024
ASO Visual Abstract: Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal AdenocarcinomaJoshua D Mitchell, Usman Panni, Nicole Fergestrom, et al.
Annals of Surgical Oncology|September 21, 2024
Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal AdenocarcinomaJoshua D Mitchell, Usman Panni, Nicole Fergestrom, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2014
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancerRoheena Z Panni, Dominic E Sanford, Brian A Belt, et al.
Cancer Research Communications|May 25, 2022
<i>In silico</i> epitope prediction analyses highlight the potential for distracting antigen immunodominance with allogeneic cancer vaccinesC Alston James, Peter Ronning, Darren Cullinan, et al.
Cancer Gene Therapy|December 16, 2017
Development of an adenovirus vector vaccine platform for targeting dendritic cellsPiyush K Sharma, Igor P Dmitriev, Elena A Kashentseva, et al.
Oncotarget|August 16, 2019
Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticlesMatthew S Strand, Bradley A Krasnick, Hua Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic CancerHui Peng, C Alston James, Darren R Cullinan, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|December 26, 2022
Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancerHui Peng, Lijin Li, Chong Zuo, et al.
Oncoimmunology|September 20, 2018
Recruitment of CCR2<sup>+</sup> tumor associated macrophage to sites of liver metastasis confers a poor prognosis in human colorectal cancerJulie G Grossman, Timothy M Nywening, Brian A Belt, et al.
Surgery|June 19, 2024
Overexpression of human DNA polymerase theta is a biomarker of aggressive and DNA repair-deficient papillary thyroid cancersC Corbin Frye, Lena Tennant, Ashley Yeager, et al.
Annals of Surgical Oncology|October 25, 2024
ASO Visual Abstract: Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal AdenocarcinomaJoshua D Mitchell, Usman Panni, Nicole Fergestrom, et al.
Annals of Surgical Oncology|September 21, 2024
Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal AdenocarcinomaJoshua D Mitchell, Usman Panni, Nicole Fergestrom, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2014
Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancerRoheena Z Panni, Dominic E Sanford, Brian A Belt, et al.
Cancer Research Communications|May 25, 2022
<i>In silico</i> epitope prediction analyses highlight the potential for distracting antigen immunodominance with allogeneic cancer vaccinesC Alston James, Peter Ronning, Darren Cullinan, et al.
Cancer Gene Therapy|December 16, 2017
Development of an adenovirus vector vaccine platform for targeting dendritic cellsPiyush K Sharma, Igor P Dmitriev, Elena A Kashentseva, et al.
Oncotarget|August 16, 2019
Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticlesMatthew S Strand, Bradley A Krasnick, Hua Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic CancerHui Peng, C Alston James, Darren R Cullinan, et al.
Pageof 6